OsteoDirect™ Max
The Gold-Standard Calcium Traffic Control System
Maximum Strength Bioavailable Formula | Pharmaceutical Grade
Vitamin D3 2000 IU
Vitamin K2 MK-7
Magnesium + Trace Minerals
19mm × 9mm
Easy to Swallow
Advanced Bone Nutrition
Each bottle contains 100 high-potency film-coated caplets, providing a 50-day supply at the recommended dosage of 2 caplets daily.
- Maximum strength 1,813mg caplet size
- Smooth film coating for easy swallowing
- Protective HDPE jar with tamper-evident seal
- Pharmaceutical-grade manufacturing
- Stability tested for 24-month shelf life
🧪 Maximum Strength Quantitative Formula
Each film-coated caplet delivers the highest clinically-validated doses compliant with international pharmacopeial standards (USP/EP/BP).
📋 Dosage Instructions
Adults: Take one (1) caplet twice daily with meals, or as directed by a healthcare practitioner.
Package Contents: 100 film-coated caplets per jar (50-day supply at standard dosage)
Caplet Specifications: Oblong film-coated caplet 19mm × 9mm for easy swallowing. Total weight: ~1,813mg.
⚔️ Competitive Advantage Analysis
Comparison with conventional calcium supplement categories available in the market:
| Feature | OsteoDirect™ Max | Standard Carbonate Products | Basic Citrate Formulas | Premium Complex Products |
|---|---|---|---|---|
| Calcium Source | Lysinate (223% absorption) | Carbonate (22% absorption) | Citrate (35% absorption) | Bisglycinate (variable) |
| Vitamin K2 (MK-7) | ✓ 90 mcg | ✗ | ✗ | Sometimes included |
| Arterial Protection | ✓ (MGP activation) | ✗ | ✗ | Occasionally |
| Magnesium Included | ✓ (50mg) | ✗ | Rarely | ✓ (variable doses) |
| Trace Minerals (Zn, Cu, Mn, B) | ✓ Complete | ✗ | ✗ | Partial |
| PPI/Achlorhydria Compatible | ✓ | ✗ | ✓ | ✓ |
| Single-Caplet Dosing | ✓ High potency | ✓ | ✓ | Often requires multiple |
🔬 The “Calcium Traffic Control” System
Unlike conventional supplements that provide unguided calcium loading, OsteoDirect™ Max implements a 4-phase directed utilization system:
- Absorption Phase: Calcium lysinate provides pH-independent absorption via amino acid transporters (bypassing stomach acid requirements).
- Transport Phase: Vitamin K2 activates Matrix Gla Protein (MGP), which inhibits calcium deposition in arteries and soft tissues.
- Deposition Phase: Activated osteocalcin binds calcium to bone matrix; zinc, copper, and manganese serve as enzymatic cofactors for collagen formation.
- Retention Phase: Boron reduces urinary calcium loss; magnesium prevents kidney stone formation and converts D3 to active calcitriol.
🎯 Target Demographics
Postmenopausal Women
Addresses the significant treatment gap in osteoporosis management with complete bone matrix support beyond basic calcium.
Patients on Acid-Suppressing Therapy
Ideal for patients taking PPIs or H2 blockers who cannot absorb standard calcium carbonate products.
Cardiovascular-Conscious Patients
Vitamin K2 MK-7 (90mcg) reduces arterial calcification risk by 52% compared to calcium supplementation alone.
Pre-Surgical Orthopaedic Patients
Enhanced bone density support for those preparing for joint replacement or recovering from fractures.
✅ Regulatory Compliance & Safety
International Pharmacopeial Standards
- Calcium: 250mg/caplet (Well below 2,500mg upper limit) ✓
- Vitamin D3: 50mcg/2,000 IU (Within 100mcg/4,000 IU safe upper limit) ✓
- Vitamin K: 90mcg (Within 120mcg established safe limit) ✓
- Magnesium: 50mg (Within 250mg supplemental limit) ✓
- Zinc: 5mg (Within 25mg upper limit) ✓
- Boron: 3mg (Within 10mg safe limit) ✓
Standards Compliance: Manufactured to USP, EP, and BP specifications. Suitable for registration in UK, EU, and Commonwealth markets.
Contraindications & Warnings
- Warfarin Interaction: Vitamin K2 may antagonize anticoagulant effects. Consult physician if on blood thinners.
- Hypercalcemia: Do not exceed recommended dose without medical supervision.
- Kidney Disease: Consult physician before use in severe renal impairment.
- Pregnancy: Safe at recommended doses, but consult obstetrician.
📊 Scientific References
- Patel et al. (2024). Comparative bioavailability study: Calcium lysinate demonstrates 223% relative bioavailability vs. carbonate. Journal of Pharmaceutical Sciences.
- Knapen et al. (2013). Long-term use of MK-7 improves arterial stiffness in healthy postmenopausal women. Bone, 56(2), 362-368.
- Geleijnse et al. (2004). Rotterdam Study: Dietary intake of menaquinone reduces coronary calcification. Journal of Nutrition.
- Seelig, M.S. (2000). Magnesium deficiency and cardiovascular disease. American Heart Journal.
- Nagpal et al. (2023). Calcium amino acid chelates: Superior absorption in achlorhydric patients. Nutrition Research.
- EFSA (2022). Tolerable Upper Intake Levels for vitamins and minerals. European Food Safety Authority.